Intelligent Bio Solutions ( (INBS) ) has provided an update.
On February 10, 2025, Intelligent Bio Solutions Inc. announced its 2024 growth achievements and its strategic plan to enter the U.S. market in 2025. In 2024, the company achieved significant revenue growth of 148% year-over-year, driven by the strong adoption of its drug screening technology. The company completed its FDA 510(k) pre-market notification in December, positioning itself to enter the U.S. drug screening market, which represents a large portion of the global demand. Rising drug positivity rates and increased safety regulations underscore the need for the company’s non-invasive testing solutions. The company anticipates continued growth, focusing on safety-critical industries and leveraging its expanding global customer base.
More about Intelligent Bio Solutions
Intelligent Bio Solutions Inc. is a medical technology company specializing in innovative, rapid, non-invasive testing solutions. Its primary product, the Intelligent Fingerprinting Drug Screening System, uses fingerprint sweat analysis to screen for drug use, offering a hygienic and cost-effective alternative to traditional testing methods. The company targets safety-critical industries and aims to expand its market share globally.
YTD Price Performance: 50.35%
Average Trading Volume: 153,031
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $10.19M
For detailed information about INBS stock, go to TipRanks’ Stock Analysis page.